Pacira Pharmaceuticals (NASDAQ:PCRX) Given a $60.00 Price Target by Royal Bank of Canada Analysts

Royal Bank of Canada set a $60.00 price objective on Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note published on Friday, November 2nd. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also commented on the stock. Canaccord Genuity set a $49.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a hold rating in a research note on Tuesday, October 2nd. Wedbush set a $85.00 target price on shares of Pacira Pharmaceuticals and gave the stock an outperform rating in a report on Monday, August 6th. Stifel Nicolaus started coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 13th. They issued a sell rating and a $41.00 target price for the company. Cowen reaffirmed a hold rating on shares of Pacira Pharmaceuticals in a report on Tuesday, July 10th. Finally, ValuEngine cut shares of Pacira Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, September 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $52.28.

NASDAQ:PCRX traded down $1.43 during mid-day trading on Friday, hitting $49.52. 389,378 shares of the company’s stock were exchanged, compared to its average volume of 555,397. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $55.00. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83. The firm has a market capitalization of $2.10 billion, a P/E ratio of -85.38 and a beta of 1.68.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The business had revenue of $83.45 million for the quarter, compared to analyst estimates of $79.87 million. During the same quarter in the previous year, the firm posted $0.11 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 23.9% on a year-over-year basis. On average, equities research analysts expect that Pacira Pharmaceuticals will post -0.02 earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, CEO David M. Stack sold 33,062 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $47.32, for a total transaction of $1,564,493.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lauren Bullaro Riker sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $54.35, for a total transaction of $54,350.00. Following the completion of the transaction, the vice president now owns 11,474 shares of the company’s stock, valued at $623,611.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,502 shares of company stock valued at $1,968,214. 5.90% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board boosted its position in shares of Pacira Pharmaceuticals by 3.0% in the second quarter. State of Wisconsin Investment Board now owns 40,600 shares of the company’s stock worth $1,301,000 after purchasing an additional 1,200 shares during the period. Rhumbline Advisers boosted its position in shares of Pacira Pharmaceuticals by 3.5% in the second quarter. Rhumbline Advisers now owns 39,897 shares of the company’s stock worth $1,279,000 after purchasing an additional 1,335 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of Pacira Pharmaceuticals by 7.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 20,548 shares of the company’s stock worth $943,000 after purchasing an additional 1,393 shares during the period. Summit Trail Advisors LLC boosted its position in shares of Pacira Pharmaceuticals by 12.9% in the first quarter. Summit Trail Advisors LLC now owns 15,103 shares of the company’s stock worth $400,000 after purchasing an additional 1,728 shares during the period. Finally, US Bancorp DE boosted its position in shares of Pacira Pharmaceuticals by 40.7% in the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after purchasing an additional 1,746 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: Price to Earnings Ratio (PE)

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply